CURATIVE TECHNOLOGIES CREATES NEW OPERATING DIVISION AND APPOINTS PRESIDENT OF NEW DIVISION
CURATIVE TECHNOLOGIES CREATES NEW OPERATING DIVISION
AND APPOINTS PRESIDENT OF NEW DIVISION
EAST SETAUKET, N.Y., Jan. 13 /PRNewswire/ -- Curative Technologies, Inc. (NASDAQ: CURE) (CTI) today announced the creation of a new operating division, Curative Wound Management Systems. James S. Crawford has been appointed president of Curative Wound Management Systems(SM).
Curative Wound Management Systems was created to adapt CTI's highly successful Wound Care Center(R) (WCC) concept to the independent provider setting. While WCCs are cooperative ventures with acute care hospitals, Curative Wound Management Systems will initially focus on comprehensive outpatient rehabilitation facilities and large medical group practices. Gerardo Canet, senior vice president of CTI and president of CTI's Wound Care Center Division, commented, "Pursuing opportunities within the independent provider model is consistent with CTI's strategic plan of developing new methods for the effective delivery of wound care products and services. The successful development of this new division will enable CTI to significantly increase the number of wound treatment facilities in operation and provide a means for accelerated revenue growth."
Over the last 18 years, Crawford has held many positions in healthcare operations and administration. Since 1987, Crawford served as vice president of CTI's Wound Care Center Division. In this position, he oversaw operations of the Northeast region. Prior to joining CTI, Crawford held various administrative posts in leading hospitals in New York and Pennsylvania, including four years as a hospital chief executive officer. He also served as vice president of Rehab Hospital Services Corporation. Crawford received a MBA in healthcare administration from Wagner College.
Commenting on Crawford's appointment, Russell B. Whitman, president of CTI, stated, "Mr. Crawford's wealth of experience in healthcare operations will contribute greatly to the successful development of our new division."
Curative Technologies, Inc. is a biopharmaceutical company engaged in the research, development, production and marketing of therapeutic products utilizing naturally occurring human growth factors. The company's first product, Procuren(R), is a topical therapeutic which promotes wound healing. Procuren is currently sold through Wound Care Centers, which are cooperative ventures with selected providers.
/CONTACT: John C. Prior of Curative Technologies, 516-689-7000, or Susan A. Noonan or Deborah J. Lawson of Noonan/Russo Communications, 212-979-9180, for Curative Technologies/
(CURE) CO: Curative Technologies, Inc. ST: New York IN: MTC SU: PS -- NY006 -- 8917 01/13/92 08:10 EST